Sanofi announced that US Food and Drug Administration (FDA) has approved subcutaneous (SC) Sarclisa (isatuximab-irfc) Escena in combination with standard-of-care regimens for the treatment of patients ...
Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena administered via the CirCLIQ® on-body injector (OBI) offers a ...
Sanofi has scored FDA approval for its subcutaneous version of Sarclisa, giving the multiple myeloma treatment a potential ...
The U.S. Food and Drug Administration (FDA) on Friday approved Sanofi SA’s SNY subcutaneous Sarclisa Escena (isatuximab-irfc) ...
Sanofi announced today that the FDA approved the delivery of its Sarclisa anticancer therapy through the Enable Injections on ...
The FDA has approved a subcutaneous version of isatuximab (Sarclisa Escena, Sanofi-Aventis) for several multiple myeloma (MM) ...
We encourage all prospective Alvernia students to apply, even if you feel you may not be eligible for assistance. The Office ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results